

PTO-1449, REPRODUCED <div style="font-size: 2em; font-weight: bold; letter-spacing: 0.5em;">FILE</div> INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)				ATTORNEY DOCKET NO. KIR95-01A		CONTINUATION OF: 08/437,533 09/285,531	
				APPLICANT Yuti Chernajovsky et al.			
				FILING DATE April 2, 1999		GROUP	
U.S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE	
AA	5,478,925	12-Dec-95	Wallach, D., et al.	530	351	07-Aug-92	
AB	5,395,760	07-Mar-95	Smith, et al.	435	240.1	10-May-90	
AC	5,470,952	28-Nov-95	Stahl, et al.	530	350	20-Oct-93	
AD							
AE							
AF							
AG							
AH							
AI							
AJ							
AK							
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO	
AL	526 905 A2	10-FEB-93	EPO				
AM	WO 92/07076	30-APR-92	PCT				
AN							
AO							
AP							
AQ							
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
AR	Lesslauer, W., et al., "Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality", <i>Eur. J. Immunol.</i> , 21:2883-2886 (1991).						
AS	Baker, D., et al., "Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins", <i>Eur. J. Immunol.</i> , 24:2040-2048 (1994).						
AT	Corcoran, A.E., et al., "Characterization of ligand binding by the human p55 tumour-necrosis-factor receptor", <i>Eur. J. Biochem.</i> , 223:831-840 (1994).						
EXAMINER				DATE CONSIDERED			
JAVID L. FITZGERALD PRIMARY EXAMINER JICUP 1800				03/24/00			

FILE

PTO-1449 REPRODUCED

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**

(Use several sheets if necessary)

ATTORNEY DOCKET NO.
KIR95-01A

CONTINUATION OF:

~~08/437,533~~ 09/285,531

APPLICANT
Yuti Chernajovsky et al.

FILING DATE
April 2, 1999

GROUP
16 46



U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AU	Kim, D.-C. and Bloedow, D.C., "Administration Route Dependency of Distribution of PEGylated Recombinant Human Tumor Necrosis Factor Binding Protein (rhTNFbp-PEG20K dimer) Following i.v. and s.c. Injection in Rats", Arch. Pharm. Res., 17(5):381-382 (1994).
	AV	Kolls, J. et al., "Prolonged and effective blockade of tumor necrosis factor activity through adenovirus-mediated gene transfer", Proc. Natl. Acad. Sci. USA, 91:215-219 (1994).
	AW	Elliott, M.J., et al., "Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α ", Arthritis & Rheumatism, 36(12):1681-1690 (1993).
	AX	Butler, D.M., et al., "TNF receptor fusion proteins are effective inhibitors of TNF-mediated cytotoxicity on human KYM-1D4 rhabdomyosarcoma cells", Cytokine, 6(6):616-623 (1994).
	AY	Bemelmans, M.H.A., et al., "Tissue distribution and clearance of soluble murine TNF receptors in mice", Cytokine, 6(6):608-615 (1994).

EXAMINER

DAVID L. FITZGERALD
PRIMARY EXAMINER
GROUP 1800

DATE CONSIDERED

03/24/50

FILE